Tiziana Life Sciences Ltd
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $157.8M
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $157.8M
- Shares outstanding
- 129.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 20, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Trading 51% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Tiziana Life Sciences Ltd.
Write a review
News about Tiziana Life Sciences Ltd
News & sentiment via Polygon.io
